Log In Get Started
Press Releases April 29, 2026 04:24 PM

BondBloxx Announces Upcoming Changes to its ETF Lineup

BondBloxx announces liquidation of multiple sector-specific high yield bond ETFs effective May 2026

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
XHY

BondBloxx Investment Management Corporation will close and liquidate six of its sector-specific high yield bond ETFs by May 15, 2026. The ETFs will cease accepting creation orders on May 15, and trading will end on the same day, with liquidation proceeding thereafter. Shareholders will receive cash based on net asset value around May 29, 2026, with recommended consultation on tax implications.

BondBloxx Announces Upcoming Changes to its ETF Lineup
XHY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • BondBloxx is discontinuing six sector-based high yield bond ETFs covering sectors such as Consumer Cyclicals, Energy, and Healthcare.
  • Last trading and creation orders for these ETFs will end on May 15, 2026, followed by liquidation of the fund portfolios.
  • Shareholders will automatically receive cash for their holdings post-liquidation; tax implications should be considered.
  • Sectors impacted include fixed income, particularly high yield corporate bonds; this may affect bond investors and related fixed income markets.

LARKSPUR, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- BondBloxx Investment Management Corporation today announced plans to close and liquidate the following ETFs based on an ongoing review of its ETF offerings:

TickerFund NameXHYCBondBloxx USD High Yield Bond Consumer Cyclicals Sector ETFXHYDBondBloxx USD High Yield Bond Consumer Non-Cyclicals Sector ETFXHYIBondBloxx USD High Yield Bond Industrial Sector ETFXHYEBondBloxx USD High Yield Bond Energy Sector ETFXHYFBondBloxx USD High Yield Bond Financial & REIT Sector ETFXHYHBondBloxx USD High Yield Bond Healthcare Sector ETFXHYTBondBloxx USD High Yield Bond Telecom, Media & Technology Sector ETF  

After the close of business on May 15, 2026, the funds will no longer accept creation orders.

The last day of trading on the NYSE Arca, Inc. for each of the funds will be May 15, 2026. On or about May 15, 2026, the funds will begin the process of liquidating their portfolios and will no longer be managed in accordance with their investment objectives.

Shareholders who do not sell or redeem their shares of any of the above-listed funds before market close on May 15, 2026 will receive cash equal to the amount of the net asset value of their shares in their brokerage accounts on or about the liquidation date of May 29, 2026.

Shareholders should consult their tax advisors about the tax implications of the liquidation of their respective funds. Although the liquidation is not expected to be a taxable event for the funds, for taxable shareholders, the automatic redemption of shares of their respective fund(s) on the liquidation date will generally be treated as a sale that may result in a gain or loss for U.S. federal income tax purposes.

About BondBloxx

BondBloxx Investment Management Corporation (“BondBloxx”) is the first ETF issuer to focus solely on fixed income, offering a range of exposures spanning U.S. Treasuries, investment grade and high yield corporate bonds, emerging markets bonds, tax-aware strategies, and private credit. To learn more about BondBloxx’s fixed income-first mission, visit BondBloxxETF.com. BondBloxx is a registered investment adviser and only transacts business in states where it is properly registered or is excluded or exempted from registration requirements.

Media Contact

Chris Sullivan
Craft & Capital
chris@craftandcapital.com

BondBloxx ETFs are distributed by Foreside Fund Services, LLC.


Risks

  • Investors holding shares past May 15 may face automatic redemption and taxable event implications, affecting taxable accounts.
  • The closure of these ETFs reduces fixed income investment options within specific sectors, potentially impacting portfolio diversification.
  • Market conditions influencing bond prices during liquidation could affect payout amounts to shareholders.

More from Press Releases

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026